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Breast cancer follow-up after a primary diagnosis: a confused picture 
 
Abstract 
The follow-up care of people diagnosed with early breast cancer varies across the world.  In the 
UK, services have evolved in an ad hoc way, with no standardized approach nationally. Some 
people are seen face to face at regular intervals, others are discharged at two years, while others 
are followed up over the telephone.  This is creating confusion for patients as to what is best 
practice. The lack of evidence to support intensive surveillance is frequently cited as the main 
reason to reduce or indeed review the benefits of face to face clinical consultations in the 
hospital/community setting. In addition, a lack of specific recommendations in current guidelines 
compounds this.  Although primary disease stage and treatment are strong indicators of survival, 
and time to recurrence (both local and distant) is extending, patterns of follow-up care in the UK 
differ depending on where you live.  Yet, European and American guidelines, where survival is 
frequently reported as being better than the UK, continue to recommend follow-up at regular 
intervals as part of their overall management approach; to ensure new and changing ways of 
treating early breast cancer are initiated, managed and monitored accordingly. Indeed their 
guidelines are increasing rather than decreasing follow-up.  While their health systems may differ, 
survival outcome reporting is not adjusted to reflect these differences.   
 
This paper provides an overview of breast cancer follow-up guidance across the world and opens 
up a debate about whether patterns of follow up care will affect survival outcomes into the future.   
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Introduction 
Survival is a key metric of overall progress in cancer control [1] and female breast cancer survival 
is better than most cancers, with 78% predicted to survive their disease for ten years or more [2].  
It is estimated [3] that there 550,000-570,000 women alive in the UK who have had a diagnosis of 
cancer. were approximately 200,286 women still alive in the UK 5 years after a breast cancer 
diagnosis. This figure is set to increase further as use of endocrine therapies are extended or 
switched between groups of drugs up to 10 years [4] and treatment for recurrent advanced 
disease becomes more targeted. 
 
Improving overall survival through treatment to reduce the risk of the breast cancer recurring still 
remains the main goal of treatment but increasingly clinicians have to balance risk of the cancer 
recurring and risk of persistent and debilitating toxicities [5]. Risks associated with the cancer 
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recurring are often difficult to quantify, or indeed explain as; “a risk is something that might happen 
in the future” [6, p.1] and predicting risk in breast cancer is not an exact science.  Research on 
patterns and risks associated with recurrence are beginning to characterise this risk by breast 
cancer subtypes such as oestrogen receptor (ER), progesterone receptor (PR), HER2/ErbB2 
receptor (HER2), the absence or all three or triple negative breast cancer (TNBC). ER negative 
breast cancers are associated with a higher risk of recurrence during the initial five years but the 
risk of recurrence risk increases in ER positive for the next 10 years, and at 15 years the risk 
equals across the subtypes [7].  This risk unfortunately can continue For those with breast cancer, 
recurrences peak in the first 2-3 years after diagnosis (10-15%) [7], but remain a constant risk 
between 3- 5 years (4.3%), and 5-9 years (4.6%) [8]  up to and beyond 20 years [8, 9].   
 
Detecting early local recurrences or contralateral breast cancer, evaluating and treating therapy-
related complications, motivating patients to continue hormonal treatments and providing 
psychological support and information in order to enable a return to normal life, whatever the new 
normal is, is consistently reported as the main purpose of follow-up care [10]. However, some 
would argue this is “aftercare” an essential part of patient care after treatment of cancer where the 
primary goal is to reduce disease burden by extending and improving quality of life [11]. The 
interchangeable use of the terms “follow-up” and “aftercare” is a source of confusion. While 
aftercare suggests a clear delineation at which treatment ends and this care begins, provided 
primarily during a period of recovery [12].  Follow-up is a more systematic approach whereby there 
is a continuation or observation of an individual aftercare is provided through contact between the 
patient and his/her treating clinicians in relation to the treated cancer. jo 
 
The treatment of breast cancer is more complex than ever.  Combining surgery +/- reconstruction, 
radiotherapy, chemotherapy, endocrine therapy or biological agents are common [13], and in most 
other areas of medicine, each would be eligible for follow-up in their own right.  Commonly the 
aftercare of one treatment used in breast cancer overlaps with the active treatment of another, and 
physical and psychosocial problems are not isolated events after any one treatment but occur from 
the moment breast cancer is suspected, through treatment and beyond. Determining the 
beginning and end of follow-up is therefore difficult and may reflect the reason why follow up 
practices have become so variable across the UK.  
 
Previous guidelines in the UK included substantial guidance about how follow-up care should be 
provided [14. 15, 16], but updated versions have been rather vague [17, 18], leading to ambiguity 
about what is recommended practice, and therefore deemed best practice. While this may reflect a 
positive trend in overall survival, it has also left patients with breast cancer receiving very different 
follow-up care, depending on the hospital or region where they live across the UK.  Although NICE 
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is widely respected, and often cited when difficult decisions in health and social care must be 
made, their guidance on follow-up is open to wide interpretation.  
 
Review of breast cancer guidelines  
The author reviewed breast cancer guidelines from across the world to understand how each 
country recommends follow-up surveillance. Guidelines for the management of early breast cancer 
were sourced from the following organisations: The National Institute for Clinical Excellence (UK) 
[18], Scottish Intercollegiate Guidelines Network (SIGN)[17], Cancer Care Ontario (CMA) [19], and 
National Comprehensive Cancer Network (NCCN, USA) [20, 21], Comprehensive Cancer Centre 
the Netherlands (DF)[22]; European Society of Medical Oncology (ESMO) [10]; Australian National 
Breast and Cancer Centre (NHMRC) [23] and The Association of Breast Surgery (UK) [24].   
 
Results 
Table 1 shows the fifteen recommendations identified for action within the guidelines. By mapping 
against these, the author has established a picture of the range of guidance provided by different 
organisations across the world (Table 2). The only consensus globally is the continuation of 
mammography. However, while the majority recommend annual mammography, BASO [24], 
based on research by Kaas et al [25] and Kokko et al. [26] concludes that this could be either 
annual or bi-annual up to 10 years. These different conclusion based on the same evidence is 
unhelpful.   
 
Four organisations recommendation switching and/or extending endocrine therapy [10. 18, 20, 
24].  However in most cases this is not linked to any detail about appointments, and/or whose 
responsibility it is to enable it to happen.  It is unusual for treatments to be changed or altered in 
other areas of medicine such as happens in asthma, cardiac, diabetic or respiratory conditions 
without a follow-up review built in to assess for efficacy, toxicity or adherence. However, it seems 
that patients with breast cancer don’t receive the same service when changes are made.  
Although some may argue that being less prescriptive is more patient centred, assumptions are 
being made that after a short consultation, woman and men fully understand the details of their 
new medication, possible toxicities, benefits and reporting.  
 
In a review of survival data by McCowan et al.[27], those with low adherence to tamoxifen had a 
shorter time to recurrence, increased medical costs and worse quality of life. In addition, a review 
of endocrine therapies by Palmieri et al [4] concluded that the extension of endocrine therapies 
beyond 5 years, including switching between groups of drugs up to 10 years will have implications 
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for managing long-term adverse events. There is no standard for how people affected by breast 
cancer can expect these changes to be implemented into their follow-up care  
 
Discussion 
This guideline review highlighted marked differences between the follow-up recommendations 
provided in the UK by SIGN [17] and NICE [18] and the more recent guidance provided by Europe 
[10] and the USA [20, 21]. While accepting that the quality of data is sometimes weak in this area, 
it is still concerning that the recommendations in the UK appear so lacking in any detail. This is 
particularly so in light of new data published by Allemani et al. [1] who suggest survival outcomes 
in the UK still lag behind many parts of the world.  While some would argue, follow-up surveillance 
is all about detecting recurrence, evidence suggests that compliance with treatments to extend 
survival [27] is improved when engagement continues through face to face consultations.    
 
In practice, the arguments for and against the continuation of follow-up surveillance are robustly 
argued on both sides, and personal preference appears to be driving the decisions within the 
same networks and regions across the UK. Can it be right that in one area patients are seen 
regularly and in another region they are discharged at 2 years – where is the evidence for this 
approach? The introduction of the recovery package [29] , a holistic approach to improve overall 
co-ordination and management to help people recover, and live well with cancer within the UK, 
should not be viewed as a substitute for follow-up, or aftercare when treatment changes, rather it 
should be viewed as complementary.  
 
The 13th St Gallen International Breast Cancer Conference expert panel [30], a highly regarded 
expert body in collating and disseminating up to date evidence about breast cancer believes that 
the provision of regular follow-up surveillance at the completion of primary treatment is appropriate 
and should continue. They support nurse specialists undertaking this care, but recommend it 
continues to be done in person rather than over the telephone. While telephone follow-up may be 
an excellent approach to provide psychological support, it cannot confirm or deny local or distant 
recurrence and this should be made clear to patients.   
 
In conclusion, many of the advances gained about how best to treat breast cancer was as a direct 
result of data gathering through follow-up surveillance. Breast cancer is entering some uncharted 
territory with the widespread use of biological agents, patients receiving several lines of treatment 
and endocrine agents being switched. There are new risks; unknown short and long term side 
effects and some complicated decisions to be made by patients and their families. If follow-up 
6 
 
practices continue to be variable, and not necessarily based on any model such as risk 
stratification, patients may miss out on the optimal treatment approach to extend survival benefit.. 
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